Improved Treatment Prognosis For Cancers
JHU REF: C12842
Invention Novelty:
This technology offers a prognostic panel derived from the gene expression of several different cancers, which was validated in multiple primary human samples. The panel, termed "AIM", differentiates patients into two tiers that correspond to a set of suggested treatment options based on the gene expression patterns for that tier. Stratification provides more effective treatment, leading to higher survival rates in patients and lower healthcare costs.
Value Proposition:
The technology offers a novel approach for diagnosing immune responses in patients with ovarian, colorectal and breast cancer, providing a classification system for treatment options on an individual patient level. Most solid tumors have low immune responses and do not respond to immunotherapy alone. This technology identifies a specific gene set that classifies these tumors into high- and low-signature immune responsive, and provides a mechanism for treating low-immune responsive tumors so that they are high-signature and thus responsive to immunotherapy.
Technical Details:
Johns Hopkins researchers analyzed patient gene sets and methylation patterns to create a prognostic panel that segregates patients into one of two labels: high and low. Patients in the low category have a lower immune signature and benefit from a combination of epigenetic drugs, chemotherapy and immunotherapy, while those in the high category may benefit from immunotherapy alone.
Stage of Development: Pre-Clinical
Data Availability: Human Breast, Ovarian and Colorectal cancer samples
Publication(s)/Associated Cases: WO 2015/120382; PMID: 24583822
